Are Clinical Biomarkers Revolutionizing the Role of Precision Medicine in Healthcare?
In the field of precision medicine, clinical biomarkers are recognized as an effective cancer-treatment technology. This is largely due to their capability to offer infectious disease diagnostics as much as at the gene level.
Significant advancements in machine learning and sequencing technology have made it possible to conduct more genomic investigations, resulting in the generation of a huge amount of data. In-depth analyses are needed to extract potential insights from the data generated by genomic projects and initiatives, which are subsequently applied to improve clinical results.
Businesses that are into biotechnology are extensively investing in research and development (R&D) to extend their respective clinical biomarkers pipeline for research and diagnostic applications. One of the main reasons behind this is to facilitate the necessity for downstream genetic data processing.
The global clinical biomarkers market exhibits huge potential to transform patient care and general well-being as the next step in the role of precision medicine in healthcare.
Integration of clinical biomarkers has become vital for the prognosis, investigation, treatment, and sustenance of human health.
The need for better healthcare products is becoming more apparent as cancer cases continue to rise. With the increasing use of inorganic growth tactics in the medical sector, numerous businesses are collaborating to develop better healthcare products and services, enabling oncologists to effectively diagnose various cancers and infectious diseases.
The number of people affected by cancer has significantly increased globally. High-fidelity diagnostic and screening procedures are some of the major factors in identifying rising incidence rates of cancer.
Another significant issue for the global healthcare sector has been the prevalence of cancer. The International Agency for Research on Cancer (IARC) released an online database known as GLOBOCAN in 2020, which provides global cancer statistics and estimates of incidence and mortality in 185 countries for 36 types of cancer with all cancer sites combined.
According to GLOBOCAN 2020, the number of cancer cases diagnosed in 2020 was 19.3 million, and almost 10.0 million died due to cancer. It predicts that the number of cancer cases will increase to 28.4 million in 2040.
According to a BIS Research Report, the global clinical biomarkers market was valued at $21.3 billion in 2021 and is expected to reach $54.2 billion by 2032, growing at a CAGR of 8.73% during the forecast period 2022–2032.
A FREE sample of this report is available here.
How are clinical biomarkers aiding the role of precision medicine in healthcare?
Clinical biomarkers are favored in the field of medicine, especially in the realm of precision medicine. They help in dose selection and prognosis efficiently.
Clinical biomarkers are majorly used in translational research and clinical diagnostics. Additionally, they have a huge potential for technological advancements in improving human health through cost-effective healthcare methods.
Contract research organizations (CROs) primarily use biomarker testing services for purposes related to bioanalysis in support of the pharmaceutical and biotechnology industry as well as research and academic institutions.
The “pipeline problem” in drug development has been addressed through biomarkers. In order to enhance diagnostic and screening effectiveness, several biomarkers for cancer detection are rapidly being developed. On this front, cancer detection biomarkers like deoxyribonucleic acid (DNA) methylation and histone modification have become increasingly prominent.
Integrated Pipeline Development through Utilization of Clinical Biomarkers
Typically, the discovery stage of biomarker research is followed by several stages leading up to the clinical application stage. A biomarker’s pipeline development typically consists of four major phases.
The procedure begins with a screening step in which a small number of samples are evaluated, followed by hundreds to thousands of samples examined for the clinical assessment of the biomarker under investigation.
The following infographic reflects the elements that must be present for the effective integration of biomarker investigations into oncology clinical trials:
- a clear and compelling hypothesis that is dependent on a compelling justification supported by evidence-based research
- a well-established assay
- a sample handling protocol and a data analysis/assessment system
- a meticulously planned and executed clinical trial.
Although data analyses of examined biomarkers have not yet reached the user-friendly standards required by the majority of clinicians and scientists, technologies such as mass spectrometry, imaging genetics, and next-generation sequencing (NGS) are redefining ways through which biomarkers are discovered and developed, as well as how they relate to human disease.
Infectious Disease Management by Incorporating Clinical Biomarkers
Clinical biomarkers are crucial in the field of managing infectious diseases. Clinical biomarkers for infectious diseases may be used to assess treatment response, differentiate between bacterial and nonbacterial infections, and predict outcomes.
Clinical biomarkers also help researchers and medical professionals comprehend how infectious or communicable diseases develop, which is crucial for efficient disease management.
The market is expected to develop on account of the rising frequency and number of deaths caused by infectious or communicable diseases.
Impediments to the Global Development of Clinical Biomarkers Market
Though the market has high growth opportunities and ways to revolutionize the role of precision medicine in healthcare, market investors are stepping back due to the requirement of expensive infrastructure and instruments and high capital investment.
Despite the significant potential of the global clinical biomarkers market, the high capital investment requirements are impeding the market’s ability to expand globally and are posing a threat to its expansion. For instance, low-income nations, such as Ethiopia, Afghanistan, and others, make up a very small portion of the global market for clinical biomarkers.
The lack of qualified, trained, and specialized professionals pose a possible threat to the global growth rate of the market, particularly in developing countries.
Conclusion
The clinical biomarkers market has huge potential and growth opportunities, which have been forecasted by scientists and researchers.
Advanced multiplex clinical biomarkers technology offers the potential to enable revolutionary precision medicine approaches and increase in research and funding to provide a favorable landscape for the market.
Clinical biomarkers have become effective tools of precision medicine by revolutionizing the traditional determination, prognostics, and diagnostics of diseases and have changed the global scenario of healthcare.
Interested to know more about the growing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at hello@bisresearch.com to learn and understand more.
